BR0115847A - Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos - Google Patents

Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos

Info

Publication number
BR0115847A
BR0115847A BR0115847-3A BR0115847A BR0115847A BR 0115847 A BR0115847 A BR 0115847A BR 0115847 A BR0115847 A BR 0115847A BR 0115847 A BR0115847 A BR 0115847A
Authority
BR
Brazil
Prior art keywords
compounds
specific compounds
adenosine receptor
receptor specific
patient
Prior art date
Application number
BR0115847-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Arlindo L Castelhano
Bryan Mckibben
David J Witter
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BR0115847A publication Critical patent/BR0115847A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0115847-3A 2000-12-01 2001-11-30 Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos BR0115847A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
PCT/US2001/045280 WO2002057267A1 (en) 2000-12-01 2001-11-30 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (1)

Publication Number Publication Date
BR0115847A true BR0115847A (pt) 2004-02-25

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115847-3A BR0115847A (pt) 2000-12-01 2001-11-30 Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos

Country Status (20)

Country Link
EP (1) EP1347980A4 (de)
JP (1) JP4579497B2 (de)
CN (1) CN1263757C (de)
AP (1) AP1893A (de)
AU (1) AU2002248151B2 (de)
BR (1) BR0115847A (de)
CA (1) CA2430577A1 (de)
CZ (1) CZ20031831A3 (de)
EA (1) EA007254B1 (de)
HU (1) HUP0400692A3 (de)
IL (1) IL155962A0 (de)
ME (1) MEP35308A (de)
MX (1) MXPA03004717A (de)
NO (1) NO327207B1 (de)
NZ (1) NZ525885A (de)
OA (1) OA13295A (de)
PL (1) PL363245A1 (de)
WO (1) WO2002057267A1 (de)
YU (1) YU42703A (de)
ZA (1) ZA200303729B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
PL204628B1 (pl) 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
EP1450811B1 (de) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
EP2198867A1 (de) * 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidinderivate als GSK-3-Inhibitoren
CA2471059C (en) 2001-12-20 2011-04-26 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
CA2502429A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
EP3421471B1 (de) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purin- und deazapurinderivate als pharmazeutische verbindungen
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
JP4705695B2 (ja) 2007-10-11 2011-06-22 アストラゼネカ アクチボラグ プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EA201070841A1 (ru) 2008-01-11 2011-02-28 Натко Фарма Лимитед НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
HUE047357T2 (hu) 2011-04-01 2020-04-28 Astrazeneca Ab Gyógyászati kezelés
KR102035361B1 (ko) 2011-11-30 2019-11-08 아스트라제네카 아베 암의 병용 치료
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CN104350056A (zh) * 2012-06-07 2015-02-11 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
JP6599852B2 (ja) * 2013-06-21 2019-10-30 ゼニス・エピジェネティクス・リミテッド ブロモドメイン阻害剤としての新規の置換された二環式化合物
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
EP3248980B1 (de) * 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Jak-hemmer
ES2734048T3 (es) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
UA118822C2 (uk) 2015-05-29 2019-03-11 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор янус-кінази
CN105771672B (zh) * 2016-04-18 2018-03-02 天津工业大学 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法
EP3594216B1 (de) * 2017-03-07 2022-04-06 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Fünfgliedrige heterocyclische aminopyrimidinverbindung und zwischenprodukt, herstellungsverfahren, pharmazeutische zusammensetzung und anwendung davon
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂
KR20210033444A (ko) * 2018-06-04 2021-03-26 엑스사이언티아 엘티디 아데노신 수용체 길항제로서 피라졸로피리미딘 화합물
CN110128316B (zh) * 2019-05-22 2021-08-31 北京大学深圳研究生院 5位取代的β-脯氨酸及其衍生物的制备方法
CN110272373B (zh) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 一种具有选择性的腺苷a1受体拮抗剂及其应用
CN114085178A (zh) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
PL204628B1 (pl) * 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
DK1246623T3 (da) * 1999-12-02 2006-11-13 Osi Pharm Inc Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
EP1450811B1 (de) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen

Also Published As

Publication number Publication date
YU42703A (sh) 2006-03-03
NO20032482L (no) 2003-07-28
CA2430577A1 (en) 2002-07-25
HUP0400692A3 (en) 2007-09-28
MXPA03004717A (es) 2004-06-30
IL155962A0 (en) 2003-12-23
MEP35308A (en) 2011-02-10
OA13295A (en) 2007-04-13
AP2003002807A0 (en) 2003-06-30
NO20032482D0 (no) 2003-06-02
CN1489590A (zh) 2004-04-14
PL363245A1 (en) 2004-11-15
HUP0400692A2 (hu) 2004-07-28
EP1347980A4 (de) 2005-02-09
NZ525885A (en) 2005-01-28
CN1263757C (zh) 2006-07-12
AU2002248151B2 (en) 2008-02-21
JP2004517896A (ja) 2004-06-17
EA007254B1 (ru) 2006-08-25
JP4579497B2 (ja) 2010-11-10
CZ20031831A3 (cs) 2004-05-12
WO2002057267A1 (en) 2002-07-25
ZA200303729B (en) 2004-05-14
EA200300628A1 (ru) 2003-12-25
EP1347980A1 (de) 2003-10-01
AP1893A (en) 2008-09-23
NO327207B1 (no) 2009-05-11

Similar Documents

Publication Publication Date Title
BR0115847A (pt) Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
BR0213358A (pt) Uso de flibanserina
BR0112476A (pt) Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
BR0011856A (pt) Agonistas de receptor a2a de n-pirazol
BR9910035A (pt) Derivados de guanidina
BR0309855A (pt) Pirazolpiridinas substituìdas com carbamato
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0011854A (pt) Agonistas de receptores de a2a de c-pirazola
FI920026A0 (fi) Farmaceutisk komposition anvaendbar som avmagringsmedicin.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0014525A (pt) Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
AR015493A1 (es) DERIVADOS CICLOHEXILOS , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UNA COMPOSICIoN uTIL PARA INHIBIR LA ACTIVIDAD IN VITRO DE NEURAMINIDASA Y PARA EL TRATAMIENTO O PROFILAXIS DE LA INFECCIoN DE INFLUENZA Y PARA TRATAIMIENTO, Y UN MÉTODO IN VITRO PARA INHIBIR LA ACTIVI
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
BR0110968A (pt) Antagonistas dos receptores de il-8
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR0316042A (pt) Kits que contêm compressa para o corpo e dispositivo térmico fixável de modo liberável
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BR9813514A (pt) Agente para tratamento de fibras queratìnicas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.